albendazole has been researched along with Loa loa Filariasis in 24 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Because of the life-threatening, post-treatment reactions that have occurred in patients with loiasis treated with ivermectin, evaluation of a short-course albendazole regimen was undertaken in a Loa-endemic region of Cameroon." | 9.11 | Human loiasis in a Cameroonian village: a double-blind, placebo-controlled, crossover clinical trial of a three-day albendazole regimen. ( Befidi-Mengue, R; Fogako, J; Folefack, A; Fualem, R; Gwanmesia, P; Horton, J; Leke, R; Nutman, TB; Pensia, E; Quakyi, I; Tabi, TE, 2004) |
| "To assess the filaricidal activity and clinical safety of albendazole in human loiasis, a double-blind, placebo-controlled study was conducted in an endemic area in Benin, Africa." | 9.07 | Albendazole in human loiasis: results of a double-blind, placebo-controlled trial. ( Ahouissou, NL; Ekoué, S; Horton, J; Klion, AD; Lanmasso, T; Massougbodji, A; Nutman, TB, 1993) |
| "Although diethylcarbamazine is curative in approximately 60% of patients who acquire loiasis as long-term visitors to an endemic area, some individuals continue to have signs and symptoms of infection despite multiple courses of diethylcarbamazine." | 7.70 | Albendazole therapy for loiasis refractory to diethylcarbamazine treatment. ( Horton, J; Klion, AD; Nutman, TB, 1999) |
| "Loiasis is a vector-borne parasitic infection endemic across many areas of Central and West Africa." | 5.56 | Encephalopathy in a patient with loiasis treated with albendazole: A case report. ( Biliotti, E; De Angelis, M; Di Bonaventura, C; Franchi, C; Gabrielli, S; Mattiucci, S; Morano, A; Taliani, G; Volpicelli, L, 2020) |
| "Sixty men and women from a loiasis endemic area in Cameroon were randomized after stratification by screening LLM (≤ 30000, 30001-50000, >50000) to three treatment arms: two doses albendazole followed by 4 doses matching placebo (n = 20), six doses albendazole (n = 20) albendazole or 6 doses matching placebo (n = 20) administered every two months." | 5.22 | Effect of Two or Six Doses 800 mg of Albendazole Every Two Months on Loa loa Microfilaraemia: A Double Blind, Randomized, Placebo-Controlled Trial. ( Gounoue, R; Kamgno, J; Kuesel, AC; Nguipdop-Djomo, P; Téjiokem, M, 2016) |
| "Because of the life-threatening, post-treatment reactions that have occurred in patients with loiasis treated with ivermectin, evaluation of a short-course albendazole regimen was undertaken in a Loa-endemic region of Cameroon." | 5.11 | Human loiasis in a Cameroonian village: a double-blind, placebo-controlled, crossover clinical trial of a three-day albendazole regimen. ( Befidi-Mengue, R; Fogako, J; Folefack, A; Fualem, R; Gwanmesia, P; Horton, J; Leke, R; Nutman, TB; Pensia, E; Quakyi, I; Tabi, TE, 2004) |
| " A trial was therefore conducted to evaluate whether a course of albendazole would bring about a slower decrease in the Loa microfilaraemia, and thus could be used as a mass 'clearing' treatment, before the distribution of ivermectin in areas where onchocerciasis and loiasis are co-endemic." | 5.10 | Effects of a 3-day regimen of albendazole (800 mg daily) on Loa loa microfilaraemia. ( Boussinesq, M; Kamgno, J; Moyou-Somo, R; Pion, SD; Tsague-Dongmo, L, 2002) |
| "To assess the filaricidal activity and clinical safety of albendazole in human loiasis, a double-blind, placebo-controlled study was conducted in an endemic area in Benin, Africa." | 5.07 | Albendazole in human loiasis: results of a double-blind, placebo-controlled trial. ( Ahouissou, NL; Ekoué, S; Horton, J; Klion, AD; Lanmasso, T; Massougbodji, A; Nutman, TB, 1993) |
| "Our findings strongly support WHO's provisional strategy of biannual mass administration of albendazole to eliminate lymphatic filariasis in areas where loiasis is co-endemic and ivermectin cannot be safely mass administered." | 3.85 | Effect of 3 years of biannual mass drug administration with albendazole on lymphatic filariasis and soil-transmitted helminth infections: a community-based study in Republic of the Congo. ( Boussinesq, M; Chesnais, CB; Fischer, PU; Missamou, F; Pion, SDS; Weil, GJ, 2017) |
| "Although diethylcarbamazine is curative in approximately 60% of patients who acquire loiasis as long-term visitors to an endemic area, some individuals continue to have signs and symptoms of infection despite multiple courses of diethylcarbamazine." | 3.70 | Albendazole therapy for loiasis refractory to diethylcarbamazine treatment. ( Horton, J; Klion, AD; Nutman, TB, 1999) |
| "Loiasis has been associated with excess mortality, but clinical studies on its treatment are scant, particularly outside endemic areas, due to the rarity of cases diagnosed." | 2.87 | Comparison of different drug regimens for the treatment of loiasis-A TropNet retrospective study. ( Angheben, A; Bisoffi, Z; Bottieau, E; Bouchaud, O; Buonfrate, D; Calleri, G; Clerinx, J; Gobbi, F; Guerriero, M; Herrera-Ávila, JP; Neumayr, A; Rodari, P; Rojo-Marcos, G; Rothe, C; Salvador, F; Treviño, B; Zammarchi, L, 2018) |
| "Loiasis is a vector-borne parasitic infection endemic across many areas of Central and West Africa." | 1.56 | Encephalopathy in a patient with loiasis treated with albendazole: A case report. ( Biliotti, E; De Angelis, M; Di Bonaventura, C; Franchi, C; Gabrielli, S; Mattiucci, S; Morano, A; Taliani, G; Volpicelli, L, 2020) |
| " When distributing microfilaricides however, considerable care is needed to minimise the risk of severe adverse events (SAEs) in areas that are co-endemic for onchocerciasis or LF and loiasis." | 1.48 | Identifying co-endemic areas for major filarial infections in sub-Saharan Africa: seeking synergies and preventing severe adverse events during mass drug administration campaigns. ( Basáñez, MG; Cano, J; O'Hanlon, SJ; Pullan, RL; Rebollo, MP; Tekle, AH; Wanji, S; Zouré, HG, 2018) |
| "Loiasis was diagnosed by means of positive IgG4 serology against Loa loa." | 1.32 | [A patient with loiasis following a trip to Central Africa]. ( Jaspers, CA; Sanders, CJ; van Kortenhof, NM, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (8.33) | 18.2507 |
| 2000's | 8 (33.33) | 29.6817 |
| 2010's | 12 (50.00) | 24.3611 |
| 2020's | 2 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Zoleko-Manego, R | 1 |
| Kreuzmair, R | 1 |
| Veletzky, L | 1 |
| Ndzebe-Ndoumba, W | 1 |
| Ekoka Mbassi, D | 1 |
| Okwu, DG | 1 |
| Dimessa-Mbadinga-Weyat, LB | 1 |
| Houtsa-Temgoua, RD | 1 |
| Mischlinger, J | 1 |
| McCall, MBB | 1 |
| Kresmner, PG | 1 |
| Agnandji, ST | 1 |
| Lell, B | 1 |
| Adegnika, AA | 1 |
| Mombo-Ngoma, G | 1 |
| Ramharter, M | 1 |
| Volpicelli, L | 1 |
| De Angelis, M | 1 |
| Morano, A | 1 |
| Biliotti, E | 1 |
| Franchi, C | 1 |
| Gabrielli, S | 1 |
| Mattiucci, S | 1 |
| Di Bonaventura, C | 1 |
| Taliani, G | 1 |
| Pion, SDS | 1 |
| Chesnais, CB | 1 |
| Weil, GJ | 1 |
| Fischer, PU | 1 |
| Missamou, F | 1 |
| Boussinesq, M | 3 |
| Peñafiel-Freire, DM | 1 |
| Herranz-Aguirre, M | 1 |
| Cano, J | 1 |
| Basáñez, MG | 1 |
| O'Hanlon, SJ | 1 |
| Tekle, AH | 1 |
| Wanji, S | 1 |
| Zouré, HG | 1 |
| Rebollo, MP | 1 |
| Pullan, RL | 1 |
| Gobbi, F | 2 |
| Bottieau, E | 1 |
| Bouchaud, O | 1 |
| Buonfrate, D | 2 |
| Salvador, F | 1 |
| Rojo-Marcos, G | 1 |
| Rodari, P | 1 |
| Clerinx, J | 1 |
| Treviño, B | 1 |
| Herrera-Ávila, JP | 1 |
| Neumayr, A | 1 |
| Calleri, G | 1 |
| Angheben, A | 2 |
| Rothe, C | 1 |
| Zammarchi, L | 1 |
| Guerriero, M | 1 |
| Bisoffi, Z | 2 |
| Tamarozzi, F | 1 |
| Degani, M | 1 |
| Metzger, WG | 1 |
| Mordmüller, B | 1 |
| Bulman, CA | 1 |
| Bidlow, CM | 1 |
| Lustigman, S | 1 |
| Cho-Ngwa, F | 1 |
| Williams, D | 1 |
| Rascón, AA | 1 |
| Tricoche, N | 1 |
| Samje, M | 1 |
| Bell, A | 1 |
| Suzuki, B | 1 |
| Lim, KC | 1 |
| Supakorndej, N | 1 |
| Supakorndej, P | 1 |
| Wolfe, AR | 1 |
| Knudsen, GM | 1 |
| Chen, S | 1 |
| Wilson, C | 1 |
| Ang, KH | 1 |
| Arkin, M | 1 |
| Gut, J | 1 |
| Franklin, C | 1 |
| Marcellino, C | 1 |
| McKerrow, JH | 1 |
| Debnath, A | 1 |
| Sakanari, JA | 1 |
| Kamgno, J | 3 |
| Nguipdop-Djomo, P | 1 |
| Gounoue, R | 1 |
| Téjiokem, M | 1 |
| Kuesel, AC | 1 |
| Moliner, JV | 1 |
| Valverde, AG | 1 |
| Sorolla, JM | 1 |
| Sgrelli, A | 1 |
| De Socio, GV | 1 |
| Papili, R | 1 |
| D'Annibale, ML | 1 |
| Baldelli, F | 1 |
| Morrone, A | 1 |
| Franco, G | 1 |
| Toma, L | 1 |
| Tchangmena, OB | 1 |
| Marangi, M | 1 |
| Tsague-Dongmo, L | 1 |
| Pion, SD | 1 |
| Moyou-Somo, R | 1 |
| van Kortenhof, NM | 1 |
| Jaspers, CA | 1 |
| Sanders, CJ | 1 |
| Tabi, TE | 1 |
| Befidi-Mengue, R | 1 |
| Nutman, TB | 3 |
| Horton, J | 3 |
| Folefack, A | 1 |
| Pensia, E | 1 |
| Fualem, R | 1 |
| Fogako, J | 1 |
| Gwanmesia, P | 1 |
| Quakyi, I | 1 |
| Leke, R | 1 |
| Stemmle, J | 1 |
| Markwalder, KA | 1 |
| Zinkernagel, AS | 1 |
| Wirth, MG | 1 |
| Grimm, F | 1 |
| Hirsch-Hoffmann, S | 1 |
| Thiel, MA | 1 |
| Franco-Alvarez de Luna, F | 1 |
| Giménez-Almenara, G | 1 |
| Vidal, E | 1 |
| Casal, M | 1 |
| Klion, AD | 2 |
| Massougbodji, A | 1 |
| Ekoué, S | 1 |
| Lanmasso, T | 1 |
| Ahouissou, NL | 1 |
| Blum, J | 1 |
| Wiestner, A | 1 |
| Fuhr, P | 1 |
| Hatz, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Host Response to Infection and Treatment in the Filarial Diseases of Humans[NCT00001230] | 500 participants (Anticipated) | Observational | 1991-03-15 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for albendazole and Loa loa Filariasis
| Article | Year |
|---|---|
Loa loa-does it deserve to be neglected?
Topics: Albendazole; Diethylcarbamazine; Filaricides; Humans; Ivermectin; Loiasis | 2014 |
[Loa loa filariasis in Italy: review of the literature with a clinical report].
Topics: Adult; Albendazole; Animals; Antinematodal Agents; Diethylcarbamazine; Diptera; Drug Therapy, Combin | 2011 |
7 trials available for albendazole and Loa loa Filariasis
| Article | Year |
|---|---|
Efficacy, safety, and tolerability of albendazole and ivermectin based regimens for the treatment of microfilaraemic loiasis in adult patients in Gabon: A randomized controlled assessor blinded clinical trial.
Topics: Adult; Albendazole; Animals; Clinical Protocols; Fishes; Gabon; Humans; Ivermectin; Loiasis | 2023 |
Comparison of different drug regimens for the treatment of loiasis-A TropNet retrospective study.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Europe; Filaricides; Humans; Ivermectin; Loa; Loias | 2018 |
Effect of Two or Six Doses 800 mg of Albendazole Every Two Months on Loa loa Microfilaraemia: A Double Blind, Randomized, Placebo-Controlled Trial.
Topics: Adolescent; Adult; Aged; Albendazole; Anthelmintics; Cameroon; Double-Blind Method; Female; Humans; | 2016 |
Effects of a 3-day regimen of albendazole (800 mg daily) on Loa loa microfilaraemia.
Topics: Adolescent; Adult; Aged; Albendazole; Animals; Cameroon; Child; Drug Administration Schedule; Female | 2002 |
Human loiasis in a Cameroonian village: a double-blind, placebo-controlled, crossover clinical trial of a three-day albendazole regimen.
Topics: Adolescent; Adult; Aged; Albendazole; Animals; Anthelmintics; Cameroon; Cross-Over Studies; Double-B | 2004 |
Albendazole in human loiasis: results of a double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Africa, Western; Aged; Albendazole; Double-Blind Method; Female; Humans; Loiasis; | 1993 |
Effect of a single dose (600 mg) of albendazole on Loa loa microfilaraemia.
Topics: Adolescent; Adult; Albendazole; Animals; Child; Dietary Fats; Female; Filaricides; Humans; Loa; Loia | 2002 |
15 other studies available for albendazole and Loa loa Filariasis
| Article | Year |
|---|---|
Encephalopathy in a patient with loiasis treated with albendazole: A case report.
Topics: Adrenal Cortex Hormones; Adult; Albendazole; Animals; Diagnosis, Differential; Filaricides; Guinea; | 2020 |
Effect of 3 years of biannual mass drug administration with albendazole on lymphatic filariasis and soil-transmitted helminth infections: a community-based study in Republic of the Congo.
Topics: Adolescent; Adult; Albendazole; Animals; Anthelmintics; Antiparasitic Agents; Child; Elephantiasis, | 2017 |
Loiasis, a Subconjunctival Manifestation.
Topics: Albendazole; Animals; Anthelmintics; Child; Conjunctivitis; Drug Therapy, Combination; Eye Infection | 2017 |
Global programme to eliminate lymphatic filariasis: progress report, 2016.
Topics: Albendazole; Anthelmintics; Diethylcarbamazine; Disease Eradication; Drug Therapy, Combination; Elep | 2017 |
Identifying co-endemic areas for major filarial infections in sub-Saharan Africa: seeking synergies and preventing severe adverse events during mass drug administration campaigns.
Topics: Africa South of the Sahara; Albendazole; Animals; Diethylcarbamazine; Drug Synergism; Drug Therapy, | 2018 |
Efficacy of High-Dose Albendazole with Ivermectin for Treating Imported Loiasis, Italy.
Topics: Adolescent; Adult; Aged; Albendazole; Antiprotozoal Agents; Biomarkers; Communicable Diseases, Impor | 2019 |
Meeting of the International Task Force for Disease Eradication, January 2014.
Topics: Advisory Committees; Africa; Albendazole; Anthelmintics; Disease Eradication; Elephantiasis, Filaria | 2014 |
Repurposing auranofin as a lead candidate for treatment of lymphatic filariasis and onchocerciasis.
Topics: Adult; Albendazole; Animals; Anthelmintics; Auranofin; Brugia malayi; Cattle; Cell Line; Diethylcarb | 2015 |
[Loa loa meningoencephalitis secondary to treatment with mebendazol].
Topics: Adolescent; Albendazole; Animals; Anthelmintics; Brain Damage, Chronic; Central Nervous System Helmi | 2011 |
A case of loiasis in Rome.
Topics: Adult; Albendazole; Anthelmintics; Anti-Inflammatory Agents; Betamethasone; Diagnosis, Differential; | 2002 |
[A patient with loiasis following a trip to Central Africa].
Topics: Albendazole; Animals; Antibodies, Helminth; Cameroon; Diagnosis, Differential; Edema; Eosinophilia; | 2003 |
[Loa loa infection of the eye -- a case series].
Topics: Adolescent; Adult; Albendazole; Animals; Cameroon; Combined Modality Therapy; Conjunctiva; Eye Infec | 2005 |
[Patient from the Republic of Congo with intermittent ocular pain].
Topics: Adult; Albendazole; Animals; Anthelmintics; Congo; Conjunctiva; Conjunctival Diseases; Humans; Loa; | 2007 |
Albendazole therapy for loiasis refractory to diethylcarbamazine treatment.
Topics: Adult; Albendazole; Anthelmintics; Diethylcarbamazine; Drug Resistance; Female; Filaricides; Humans; | 1999 |
Encephalopathy following Loa loa treatment with albendazole.
Topics: Albendazole; Animals; Anthelmintics; Blood Chemical Analysis; Delirium; Electroencephalography; Ence | 2001 |